Global InformationBovhyaluronidase azoximer information
| Clinical data | |
|---|---|
| Pronunciation | Bovhyaluronidase azoximer (bovhyaluronidasum azoximerum) |
| Trade names | Longidaze |
| Routes of administration | intramuscular injection |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | not less than 90% |
| Elimination half-life | 36 hours |
| Excretion | renal |
Bovhyaluronidase azoximer, sold under the brand name Longidaze, is a conjugate of proteolytic enzyme hyaluronidase with high- molecular weight copolymer that forms a component of combination therapy regimens for treatment and prevention of diseases associated with connective tissue hyperplasia.[1] The most frequently observed adverse reactions seen with bovhyaluronidase azoximer include pain at site of injection and injection site reactions such as skin redness, itching and oedema. Local reactions typicaly resolve themselves in 48–72 hours.[medical citation needed]
- ^ Russian Ministry of Healthcare, The Ministry of Healthcare of the Russian Federation (2016). ""Instruction of the medicinal use of medicinal product Longidaze"" (PDF). Archived (PDF) from the original on 2019-06-13.